RxDoctor Payments DataLook up a doctor →

Swaraj Singh, MD

Vascular Neurology · Phoenix, AZNPI 1851599682

Payments from drug & device makers

$15,704in general payments, 2019–2025

Across 1,077 payments — averaging $14.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • UCB, Inc.$1K
  • Novartis$1K
  • Genentech USA, Inc.$1K
  • Acadia Pharmaceuticals Inc$986
  • Teva Pharmaceuticals USA, Inc.$760
  • plus $8K from 53 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)170$2,251
UCB, Inc.135$1,397
Novartis86$1,141
Genentech USA, Inc.50$1,049
Acadia Pharmaceuticals Inc85$986
Teva Pharmaceuticals USA, Inc.54$760
Biogen52$754
Amneal Pharmaceuticals LLC48$678
AstraZeneca27$612
Argenx US, Inc.53$561
SK Life Science, Inc.28$481
Lilly USA, LLC32$472
EMD Serono, Inc.26$462
Eisai Inc.23$458
Pfizer25$434
Medtronic(2 entities)14$422
Bristol Myers Squibb23$380
Amgen(2 entities)20$341
Ipsen Biopharmaceuticals, Inc12$219
Neurocrine Biosciences, Inc.10$195
Lundbeck LLC8$163
Abbott7$149
Supernus Pharmaceuticals, Inc.14$140
Merz North America, Inc.6$138
Aucta Pharmaceuticals, Inc.9$79
E.r. Squibb & Sons, L.L.C.4$77
Harmony Biosciences LLC3$66
Neurelis, Inc.4$59
Livanova USA, Inc.4$55
Tanabe Pharma America, Inc.4$53
TG Therapeutics, Inc.3$53
Biohaven Pharmaceuticals, Inc.3$52
Takeda Pharmaceuticals U.S.A., Inc.2$46
Axsome Therapeutics, Inc.2$44
Kyowa Kirin, Inc.3$42
Sumitomo Pharma America, Inc.3$37
Nevro Corp.1$29
Acorda Therapeutics, Inc2$26
Sanofi-aventis U.S. LLC1$25
C2n Diagnostics, LLC1$25
Vertiflex, Inc.1$24
MDD US Operations, LLC1$19
Corium, LLC2$19
Shire North American Group Inc1$18
Smith+Nephew1$18
Alnylam Pharmaceuticals Inc.1$17
Aprecia Pharmaceuticals, LLC1$17
Mallinckrodt Enterprises LLC1$16
GE HealthCare1$15
Jazz Pharmaceuticals Inc.1$15
Scilex Pharmaceuticals Inc.1$15
Vanda Pharmaceuticals Inc.1$14
Biohaven Pharmaceutical Holding Company Ltd.1$14
Fidia Pharma USA Inc.1$14
Mallinckrodt Hospital Products Inc.1$13
Promius Pharma LLC1$13
Banner Life Sciences, LLC1$13
Bausch Health US, LLC1$12
Zyla Life Sciences, Inc.1$12

How this compares

Too few vascular neurology providers in Arizonato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$1,056,787
Medicare patients
818
Services billed
40,901

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other vascular neurology in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →